POLYMORPHS, SOLVATES, AND HYDRATE OF 5-(4'-FLUORO-2'-OXO-1',2'-DIHYDROSPIRO[CYCLOPROPANE-1,3'-INDOL]-5'-YL)-1--METHYL-1H-PYRROLE-2-CARBONITRILE

• US 20080312306A1
• Filed: 06/13/2008
• Published: 12/18/2008
• Est. Priority Date: 06/15/2007
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Niu, Yuping, Mirmehrabi, Mahmoud, Tadayon, Abdolsamad, Wu, Yanzhong, Considine, John Leo, Deshmukh, Subodh, Liang, Jennifer Q.
• Application Number:
  US12/138,852
• Publication Number:
  US 20080312306A1
• Time in Patent Office: Days
• US Class Current: 514/409
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 207/34 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

Novel polymorph Form II and III, solvate Forms I, II, III, and IV, and the hydrate of 5-(4′-fluoro-2′-oxo-1′,2′-dihydrospiro[cyclopropane-1,3′-indol]-5′-yl)-1-methyl-1H-pyrrole-2-carbonitrile are provided, as are methods for preparing the same. Pharmaceutical compositions and kits containing these novel polymorphs, solvates, and hydrate, and combinations thereof are further provided, as are methods of contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, hormone-dependent carcinomas; treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; or treating symptoms of premenstrual syndrome using one or more of these polymorphs, solvates, or hydrate.

Claims

1. A form of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile selected from the group consisting of;

(i) polymorph Form II of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile comprising;

(a) an X-ray diffraction peak pattern comprising a peak at 2θ

of about 12.5°

at greater than about 95% relative intensity; and

(b) a differential scanning calorimetry thermogram having an endothermic peak with a T_onset of about 223°

C.;

(ii) polymorph Form III of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile comprising;

(c) an X-ray diffraction peak pattern comprising a peak at 2θ

of about 18.7°

at greater than about 95% relative intensity; and

(d) a differential scanning calorimetry thermogram having an endothermic peak with a T_onset of about 220.5°

C.;

(iii) solvate Form I of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile comprising an X-ray diffraction peak pattern comprising a peak at 2θ

of about 14.8°

at greater than about 95% relative intensity;

(iv) solvate Form II of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile comprising;

(e) an X-ray diffraction peak pattern comprising a peak at 2θ

of about 9.5°

at greater than about 95% relative intensity; and

(f) a differential scanning calorimetry thermogram having an endothermic peak with a T_onset of about 221.5°

C., 95.3°

C., or a combination thereof;

(v) solvate Form III of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile comprising;

(g) an X-ray diffraction peak pattern comprising a peak at 2θ

of about 11.9°

at greater than about 95% relative intensity; and

(h) a differential scanning calorimetry thermogram having an endothermic peak with a T_onset of about 224.6°

C., 103.2°

C., or a combination thereof;

(vi) solvate Form IV of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile comprising an X-ray diffraction peak pattern comprising a peak at 2θ

of about 22.3°

at greater than about 95% relative intensity; and

(vii) hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile comprising;

(j) an X-ray diffraction peak pattern comprising a peak at 2θ

of about 8.4°

at greater than about 95% relative intensity; and

(k) a differential scanning calorimetry thermogram having one endothermic peak with a T_onset of about 223°

C. and a second endothermic peak with a T_onset of about 111°

C.

2. The form according to claim 1 which is polymorph Form II and wherein said X-ray diffraction pattern further comprises one or more peaks at 2θ

of about 14.1°

, 18.9°

, and 24.3°

.

3. The form according to claim 1, which is polymorph Form II and comprises short, rod-like particles.

4. The form according to claim 1 which is solvate Form I and wherein said X-ray diffraction pattern further comprises one or more peaks at 2θ

of about 13.1°

, 13.9°

, 14.3°

, 24.5°

, or 25.4°

.

5. The form according to claim 1 which is solvate Form I and comprises dimethylformamide.

6. The form according to claim 1 which is solvate Form II and wherein said X-ray diffraction pattern further comprises one or more peaks at 2θ

of about 7.6°

, 14.7°

, 21.7°

, and 22.3°

.

7. The form according to claim 1 which is solvate Form II and comprises dimethylformamide.

8. The form according to claim 1 which is solvate Form III and wherein said X-ray diffraction pattern further comprises one or more peaks at 2θ

of about 7.6°

, 8.4°

, 11.6°

, 13.4°

, 15.1°

, 15.7°

, 16.9°

, 18.3°

, 18.6°

, 19.9°

, 22.5°

, 22.8°

, 25.8°

, or 26.4°

.

9. The form according to claim 1 which is solvate Form III and comprises toluene.

10. The form according to claim 1 which is solvate Form IV and comprises a nuclear magnetic spectrum comprising peaks at about δ

0.88 and 1.25.

11. The form according to claim 1 which is solvate Form IV and wherein said X-ray diffraction pattern further comprises one or more peaks at 2θ

of about 7.4°

, 8.1°

, 14.8°

, and 21.8°

.

12. The form according to claim 1 which is solvate Form IV and comprises heptane.

13. The form according to claim 1 which is the hydrate and wherein said X-ray diffraction pattern further comprises a peak at 2θ

of about 11.2° and

16.9°

.

14. The form according to claim 1 which is the hydrate and comprises thin, plate-like and needle-like particles.

15. The form according to claim 1 which is the hydrate and comprises about 4 to 5% water.

16. The form according to claim 1 which is the hydrate and is hygroscopic.

18. A pharmaceutical composition comprising one or more of polymorph Form II, polymorph Form III, solvate Form I, solvate Form II, solvate Form III, solvate Form IV, or the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1 and a pharmaceutically acceptable carrier.

19. A kit comprising one or more of polymorph Form II, polymorph Form III, solvate Form I, solvate Form II, solvate Form III, solvate Form IV, or the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1 and a carrier suitable for administration to a mammalian subject.

20. A method of preparing a pharmaceutical composition comprising one or more of polymorph Form II, polymorph Form III, solvate Form I, solvate Form II, solvate Form III, solvate Form IV, or the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising combining one or more of polymorph Form II, polymorph Form III, solvate Form I, solvate Form II, solvate Form III, solvate Form IV, or the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile and one or more of;

(i) a metal chelator;

(ii) a pH adjuster;

(iii) a surfactant;

(iv) at least one filler;

(v) a binder;

(vi) a disintegrant; and

(vii) a lubricant.

21. A method of contraception;

treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas;

providing hormone replacement therapy;

stimulating food intake;

synchronizing estrus;

or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder, said method comprising administering to a female in need thereof one or more of polymorph Form II, polymorph Form III, solvate Form I, solvate Form II, solvate Form III, solvate Form IV, or the hydrate of claim 1.

22. The method according to claim 21, wherein said fibroids are uterine fibroids.

23. The method according to claim 21, wherein said carcinomas are selected from the group consisting of carcinomas of the endometrium, breast, uterine, ovarian and prostate cancer.

24. A method for preparing polymorph Form II of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising slurrying the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in ethyl acetate, methanol, or isopropylalcohol at room temperature for about 60 hours.

25. A method for preparing polymorph Form II of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising slurrying polymorph Form I of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in ethyl acetate, methanol, or isopropylalcohol at room temperature for about 6 days.

26. A method for preparing polymorph Form III of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising;

(i) dissolving the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in acetone;

(ii) heating the product of step (i) to about 50°

C.; and

(iii) evaporating said acetone from step (ii).

27. A method for preparing solvate Form I of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising slurrying the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in dimethylformamide at about room temperature for at least about 60 hours.

28. The method according to claim 27, wherein the slurrying is performed for more than about 60 hours.

29. A method for preparing solvate Form II of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising;

(i) dissolving the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in dimethylformamide;

(ii) heating the product of step (i) to about 50°

C.; and

(iii) evaporating said dimethylformamide from step (ii) under vacuum.

30. A method for preparing solvate Form III of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising slurrying the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in toluene.

31. The method according to claim 30, wherein said slurrying is performed for more than 60 hours.

32. A method for preparing solvate Form IV of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising;

(i) dissolving the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in tetrahydrofuran; and

(ii) adding excess heptane to the product of step (i) quickly with stirring.

33. The method according to claim 32, wherein the tetrahydrofuran to heptane volume ratio is 1:

1.

34. A method for preparing the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising slurrying Form I of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in water at room temperature for more than a week.

35. A method for preparing solvate Form I of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising slurrying the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in dimethylformamide at about room temperature for at least about 60 hours.

36. The method according to claim 35, wherein the slurrying is performed for more than about 60 hours.

37. A method for preparing polymorph Form I of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile of claim 1, said method comprising slurrying the hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile in ethyl acetate, methanol, or isopropylalcohol at room temperature for about 60 hours.

17. A micronized hydrate of 5-(4′

-fluoro-2′

-oxo-1′

,2′

-dihydrospiro[cyclopropane-1,3′

-indol]-5′

-yl)-1-methyl-1H-pyrrole-2-carbonitrile which has a median particle size less than about 10 μ

m.